A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.
Experimental Drug Gaining Traction Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are encouraged to contact these profiles directly for source information, while also obtaining discount codes.
Thriving Commerce on Social Networks
Additionally, a robust market exists on messaging services, where communities with numerous of participants share “before and after” images, administration instructions and claims of next-day British shipping. Vendors market the substance there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and glucagon. Preliminary studies suggest it could help patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.
Healthcare Experts Express Worries
Nevertheless, doctors and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering products of unknown origin.
Some professionals said the demand for retatrutide could be linked to the increasing cost of licensed weight loss treatments such as Mounjaro.
Legal Position and Implementation
Selling the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or supplied for human use under the British medical regulations.
Some content creators attempt to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still violate medicines, advertising, and consumer laws, potentially leading to fines, legal action or prison.
Service Reaction and Content Removal
Based on the social media company, the service has taken down problematic content and banned associated keywords and query recommendations. The company stated it was committed to keeping the platform safe and investing in enhancing enforcement strategies.
Online Marketplace Operations
Research also found groups with up to nine thousand members selling retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Typing “retatrutide” immediately brings up channels with numerous of users, populated with images of slimming results, glowing reviews and detailed guides for mixing or administering at residence.
After moments of joining one group, a seller posted contact information, where most purchases take place. The vendor sent an instruction manual and promised delivery within two days. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None asked about body mass, medical conditions or previous experience.
Item Details and Pricing
Inside these groups, posts show black plastic parcels with Royal Mail stickers, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at home with sterile water, or pre-filled pens usually priced at 160 pounds for 20 milligrams. When questioned how much time a pen should last, vendors give contradictory responses varying between a several days to “depends on your body”.
Platform Moderation and Security Measures
A representative for Telegram stated it actively moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering materials they cannot confirm. Even if the research behind this drug is sound, these digital products may not contain what they claim,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of an online medical service connected the surge in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With costs rising, patients are turning to social media. But fake treatments are highly dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.
Her staff has already seen patients injured by self-injection from unverified suppliers. “We recognize the frustration, but buying from Telegram or WhatsApp is taking chances with your health,” stated Wyllie. “These substances could be impure or improperly measured.”
Producer Statement
A spokesperson from the pharmaceutical company stated retatrutide was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency anywhere in the world. “Consequently at this time no one can market [it] for human use,” they said, adding that any item “misleadingly claiming itself as a company experimental substance not yet authorized … may subject users to possibly serious medical dangers”.
